Experience

Davis Polk advised Anacor Pharmaceuticals, Inc. in connection with its offering of $287.5 million aggregate principal amount of its 2.00% convertible senior notes due 2023 to qualified…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in the $70.5 million initial public offering by Corvus Pharmaceuticals, Inc. of 4,700,000…

Davis Polk advised Hypermarcas S.A. in connection with its cash tender offer to purchase any and all of its outstanding $312.6 million 6.5% senior notes due 2021 and consent solicitation…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. (“NuVasive”) of $650 million aggregate principal amount of its 2.25% convertible senior…

Davis Polk advised the counterparty in connection with an accelerated share repurchase transaction entered into between the counterparty and Pfizer Inc. (“Pfizer”), pursuant to which Pfizer…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Invacare Corporation of $130 million aggregate principal amount of its 5.00%…

Davis Polk advised the sole underwriter in connection with the SEC-registered follow-on public offering of 4,444,445 ordinary shares sold by Quotient Limited (“Quotient”). Total gross…

Davis Polk advised the joint book-running managers and representatives of the underwriters in the $182.2 million initial public offering by BeiGene, Ltd. of 7,590,000 American Depositary…

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $108.6 million initial public offering of 6,785,000 shares of common…

Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with a Rule 144A offering by Novavax, Inc. of an aggregate principal amount of …